These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 26960887)

  • 21. News of the polypill.
    Marshall T
    BMJ; 2008 Oct; 337():a2160. PubMed ID: 18936068
    [No Abstract]   [Full Text] [Related]  

  • 22. The cardiovascular polypill in high-risk patients.
    Lafeber M; Spiering W; Singh K; Guggilla RK; Patil V; Webster R;
    Eur J Prev Cardiol; 2012 Dec; 19(6):1234-42. PubMed ID: 22019908
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The heart of women is not like it used to be, either. Cardiovascular risk factors and their treatment. Interview with Dr. Gábor Simonyi by Anna Radnai].
    Simonyi G
    Orv Hetil; 2013 Mar; 154(10):399-400. PubMed ID: 23461983
    [No Abstract]   [Full Text] [Related]  

  • 24. The polypill.
    Drown DJ
    Prog Cardiovasc Nurs; 2003; 18(4):197. PubMed ID: 14605522
    [No Abstract]   [Full Text] [Related]  

  • 25. Prime time for a polypill after myocardial infarction?
    Fuster V
    Nat Clin Pract Cardiovasc Med; 2009 Feb; 6(2):83. PubMed ID: 19174823
    [No Abstract]   [Full Text] [Related]  

  • 26. [Ramipril plus amlodipine and lisinopril plus amlodipine fixed dose combinations and patient's adherence].
    Simonyi G; Ferenci T
    Orv Hetil; 2016 Jan; 157(1):30-4. PubMed ID: 26708684
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polypill opens a path for improving adherence.
    Reddy KS
    J Am Coll Cardiol; 2014 Nov 18-25; 64(20):2083-5. PubMed ID: 25457397
    [No Abstract]   [Full Text] [Related]  

  • 28. The evening versus morning polypill utilization study: the TEMPUS rationale and design.
    Lafeber M; Grobbee DE; Bots ML; Thom S; Webster R; Rodgers A; Visseren FL; Spiering W
    Eur J Prev Cardiol; 2014 Apr; 21(4):425-33. PubMed ID: 23382539
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) in clinical practice in patients with vascular diseases or type 2 diabetes mellitus.
    Lafeber M; Grobbee DE; Spiering W; van der Graaf Y; Bots ML; Visseren FL;
    Eur J Prev Cardiol; 2013 Oct; 20(5):771-8. PubMed ID: 22649123
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Fixed-dose compounds and the secondary prevention of ischemic heart disease].
    Fuster V; Sanz G
    Rev Esp Cardiol; 2011 Jul; 64 Suppl 2():3-9. PubMed ID: 21807282
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Cardiovascular prevention: could the polypill reduce the risk of clinical inertia and poor compliance?].
    Scheen AJ; Lefebvre PJ; Kulbertus H
    Rev Med Liege; 2010; 65(5-6):267-72. PubMed ID: 20684405
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Polypill and global cardiovascular health strategies.
    Sanz G; Fuster V
    Semin Thorac Cardiovasc Surg; 2011; 23(1):24-9. PubMed ID: 21807295
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The concept of the polypill in the prevention of cardiovascular disease.
    Wiley B; Fuster V
    Ann Glob Health; 2014; 80(1):24-34. PubMed ID: 24751562
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discontinuation of aspirin for secondary prevention.
    Biondi-Zoccai G; Landoni G
    BMJ; 2011 Jul; 343():d3942. PubMed ID: 21771830
    [No Abstract]   [Full Text] [Related]  

  • 35. [Is the "polypill" in cardiovascular prevention an option].
    Flatz A; Renard D; von Elm E
    Praxis (Bern 1994); 2015 Mar; 104(6):305-6. PubMed ID: 25758972
    [No Abstract]   [Full Text] [Related]  

  • 36. Preservation of bioavailability of ingredients and lack of drug-drug interactions in a novel five-ingredient polypill (polycap): a five-arm phase I crossover trial in healthy volunteers.
    Patel A; Shah T; Shah G; Jha V; Ghosh C; Desai J; Khamar B; Chakraborty BS
    Am J Cardiovasc Drugs; 2010; 10(2):95-103. PubMed ID: 20334446
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Polypill: From Promise to Pragmatism.
    Huffman MD
    PLoS Med; 2015 Aug; 12(8):e1001862. PubMed ID: 26263422
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Letter to the editor: Treating nonalcoholic fatty liver disease with statins. Are all statins equal?
    Athyros VG; Katsiki N; Mikhailidis DP
    Am J Physiol Gastrointest Liver Physiol; 2017 Jun; 312(6):G681-G682. PubMed ID: 28596414
    [No Abstract]   [Full Text] [Related]  

  • 39. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.
    Patel A; Cass A; Peiris D; Usherwood T; Brown A; Jan S; Neal B; Hillis GS; Rafter N; Tonkin A; Webster R; Billot L; Bompoint S; Burch C; Burke H; Hayman N; Molanus B; Reid CM; Shiel L; Togni S; Rodgers A;
    Eur J Prev Cardiol; 2015 Jul; 22(7):920-30. PubMed ID: 24676715
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polypill strategy at the heart of cardiovascular secondary prevention.
    Ibañez B; Castellano JM; Fuster V
    Heart; 2019 Jan; 105(1):9-10. PubMed ID: 30030331
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.